Evidence map›Paper›PMID 22424230›Full record

ReviewCell2012

Alzheimer mechanisms and therapeutic strategies.

Yadong Huang, Lennart Mucke

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 814 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
814citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

814 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. A Review on the Pathophysiology of Alzheimer's Disease.Current protein & peptide science · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

754 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yadong HuangGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Lennart Mucke

Funding

Tissue Culture CoreP01AG022074 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MASLIAH, ELIEZER · 2003 to 2012
$27.0M
Transgenic Models to Study Alzheimer's DiseaseR37AG011385 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2002 to 2011
$4.9M
TRANSGENIC MODELS TO SUDY ALZHEIMERS DISEASER01AG011385 · NIA · SCRIPPS RESEARCH INSTITUTE · PI MUCKE, LENNART · 1992 to 2017
$3.2M
NIA NIH HHS AG011385NIA NIH HHS AG022074NIA NIH HHS P01 AG022074
6 · The paper itself

Abstract

There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease, but research advances over the past three decades could change this gloomy picture. Genetic studies demonstrate that the disease has multiple causes. Interdisciplinary approaches combining biochemistry, molecular and cell biology, and transgenic modeling have revealed some of its molecular mechanisms. Progress in chemistry, radiology, and systems biology is beginning to provide useful biomarkers, and the emergence of personalized medicine is poised to transform pharmaceutical development and clinical trials. However, investigative and drug development efforts should be diversified to fully address the multifactoriality of the disease.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsCognitiongamma-Aminobutyric AcidHumansAmyloid beta-Protein Precursorgamma-Aminobutyric Acid

Identifiers

PMID22424230
PMCPMC3319071

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.